MoonLake Immunotherapeutics (NASDAQ: MLTX) is a clinical-stage biotech developing nanobody therapies for inflammatory diseases. Its lead candidate, sonelokimab, is in Phase 3 trials for hidradenitis suppurativa and psoriatic arthritis. With fast-track potential and a differentiated platform, MoonLake is a high-momentum biotech name in immunology.